Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Invex Therapeutics Ltd. ( (AU:IXC) ) has issued an announcement.
Invex Therapeutics reported new data from its research collaboration with Tessara Therapeutics, showing that exenatide demonstrated multiple potentially beneficial effects in Tessara’s ADBrain™ model of Alzheimer’s disease. In the latest analysis, exenatide reduced neurofilament light chain levels by about 40%, lowered pro‑inflammatory cytokines IL-6 and IL-8, and improved measures of neural network complexity such as branching and branch length, while not significantly affecting phosphorylated tau or insulin‑dependent glucose uptake under the tested conditions; the company views these findings as supportive of exenatide’s potential therapeutic benefit early in Alzheimer’s disease and intends to investigate the observed effects on amyloid‑beta burden further.
The most recent analyst rating on (AU:IXC) stock is a Sell with a A$0.11 price target. To see the full list of analyst forecasts on Invex Therapeutics Ltd. stock, see the AU:IXC Stock Forecast page.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is an ASX-listed biopharmaceutical company focused on developing and commercialising exenatide for neurological conditions associated with raised intracranial pressure, targeting unmet needs in disorders where intracranial pressure and neurodegeneration play a key role.
Average Trading Volume: 75,585
Technical Sentiment Signal: Buy
Current Market Cap: A$8.27M
See more data about IXC stock on TipRanks’ Stock Analysis page.